Bibliographic Details
| Title: |
Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment‐resistant depression. |
| Authors: |
Martinotti, Giovanni, Dell'Osso, Bernardo, Di Lorenzo, Giorgio, Maina, Giuseppe, Bertolino, Alessandro, Clerici, Massimo, Barlati, Stefano, Rosso, Gianluca, Di Nicola, Marco, Marcatili, Matteo, d'Andrea, Giacomo, Cavallotto, Clara, Chiappini, Stefania, De Filippis, Sergio, Nicolò, Giuseppe, De Fazio, Pasquale, Andriola, Ileana, Zanardi, Raffaella, Nucifora, Domenica, Di Mauro, Stefania |
| Source: |
Bipolar Disorders; May2023, Vol. 25 Issue 3, p233-244, 12p, 4 Charts, 2 Graphs |
| Subject Terms: |
MENTAL depression, BIPOLAR disorder, HYPOMANIA, AFFECTIVE disorders, INTRANASAL medication, DISEASE duration |
| Abstract: |
Background: Bipolar depression accounts for most of the disease duration in type I and type II bipolar disorder (BD), with few treatment options, often poorly tolerated. Many individuals do not respond to first‐line therapeutic options, resulting in treatment‐resistant bipolar depression (B‐TRD). Esketamine, the S‐enantiomer of ketamine, has recently been approved for treatment‐resistant depression (TRD), but no data are available on its use in B‐TRD. Objectives: To compare the efficacy of esketamine in two samples of unipolar and bipolar TRD, providing preliminary indications of its effectiveness in B‐TRD. Secondary outcomes included the evaluation of the safety and tolerability of esketamine in B‐TRD, focusing on the average risk of an affective switch. Methods: Thirty‐five B‐TRD subjects treated with esketamine nasal spray were enrolled and compared with 35 TRD patients. Anamnestic data and psychometric assessments (Montgomery‐Asberg Depression Rating Scale/MADRS, Hamilton‐depression scale/HAM‐D, Hamilton‐anxiety scale/HAM‐A) were collected at baseline (T0), at one month (T1), and three months (T2) follow up. Results: A significant reduction in depressive symptoms was found at T1 and T2 compared to T0, with no significant differences in response or remission rates between subjects with B‐TRD and TRD. Esketamine showed a greater anxiolytic action in subjects with B‐TRD than in those with TRD. Improvement in depressive symptoms was not associated with treatment‐emergent affective switch. Conclusions: Our results supported the effectiveness and tolerability of esketamine in a real‐world population of subjects with B‐TRD. The low risk of manic switch in B‐TRD patients confirmed the safety of this treatment. [ABSTRACT FROM AUTHOR] |
|
Copyright of Bipolar Disorders is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
|
Full text is not displayed to guests. |
Login for full access.
|
